Skip to main content
. 2025 Jan 8;28(1):pyaf001. doi: 10.1093/ijnp/pyaf001

Table 1.

Pharmacokinetic parameters for N,N-DMT and its metabolites, and harmine and its metabolite in the DMT + harmine condition and harmine + placebo condition based on non-compartmental analyses.

Condition
marker
Cmax (ng/mL) tmax (h) t1/2 (h) AUCall (ng × h/mL) AUCinf (ng × h/mL)
DMT + harmine
 DMT 22.1 (7.1) 2.7 (0.5) 0.6 (0.3) 56.6 (17.3) 59.9 (19.4)
 DMT-N-oxide 21.0 (7.0) 3.2 (0.6) 1.2 (0.4) 55.4 (17.8) 69.2 (22.1)
 NMT 0.4 (0.3) 3.3 (0.7) 2.4 (2.4) 1.0 (0.6) 1.6 (1.6)
 3-IAA 2912.2 (1442.8) 4.1 (0.6) - 7578.7 (3250.2) -
 Harmine 32.5 (12.2) 1.6 (0.6) 1.4 (0.7) 89.1 (36.1) 104.1 (48.0)
 Harmole 12.0 (8.3) 1.6 (1.2) 1.8 (1.4) 29.5 (17.6) 36.8 (20.6)
Harmine + placebo
 Harmine 33.5 (17.6) 1.4 (0.4) 1.5 (0.8) 83.5 (47.7) 99.5 (63.8)
 Harmole 12.5 (7.5) 1.6 (0.6) 2.0 (0.8) 26.4 (13.2) 32.6 (15.6)

Means and SDs (displayed in brackets) are shown. Temporal values refer to the administration time of DMT or harmine.

Abbreviations: AUCall, area under the plasma concentration-time curve from time zero to last time point; AUCinf, area under the plasma concentration-time curve from time zero to infinity; Cmax, estimated maximum plasma concentration; DMT, N,N-dimethyltryptamine; 3-IAA, indole-3-acetic acid; NMT, N-methyltryptamine; t1/2‐, estimated plasma elimination half-life; tmax, estimated time to reach Cmax.